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Purpose: We purposed to assess the effects of adjuvant chemotherapy (ACH) on survival outcomes in patients with locally ad-
vanced muscle-invasive bladder cancer (MIBC) who are treated with radical cystectomy (RC). 
Materials and Methods: Literature search was conducted in PubMed, Embase, and Cochrane library databases for all articles that 
were published until February 2018. Systematic review and meta-analysis were performed by pooling the randomized controlled 
trials (RCTs) that compared patients with locally advanced MIBC who received ACH after RC to those who underwent cystectomy 
alone. Endpoints were progression free survival (PFS) and overall survival (OS).
Results: Four RCTs with a total of 490 patients were selected for the analysis. These four trials included patients with locally ad-
vanced MIBC. Pooled HRs for PFS and OS across the studies were 0.48 (95% confidence interval [CI], 0.39–0.60; p<0.00001) and 
0.63 (95% CI, 0.48–0.83; p=0.0009), respectively. Absolute increases in PFS and OS for locally advanced MIBC were 17% and 10%, 
respectively (i.e., equivalent to numbers needed to treat of 5.9 and 10). 
Conclusions: ACH following RC may improve the survival outcomes of locally advanced MIBC patients. Beneficial effect of ACH 
might be more marked in patients with locally advanced MIBC when comparing the previously reported meta-analysis with all 
MIBC patients.
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INTRODUCTION
Radical cystectomy (RC) is the standard surgical therapy 
for patients with muscle-invasive bladder cancer (MIBC) 
[1,2]. In patients who undergo RC only, 5-year survival 
rate for bladder cancer can be up to 80% for lymph node–
negative and organ-limited disease. Survival rate decreases 
to 40% in patients with extravesical extension of bladder 
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cancer, and it can decrease to 15% to 35% if  lymph node 
metastases are present [1,3,4]. The primary cause of  poor 
survival rates in patients with locally advanced MIBC may 
be systemic occult micrometastatic disease present at the 
time of RC; preoperative imaging studies cannot detect these 
micrometastases [5]. These findings suggest that extended 
use of neoadjuvant or adjuvant systemic chemotherapies 
that eradicate micrometastatic disease should be considered 
in most patients with locally advanced MIBC, as RC alone 
may not be effective for disease management [6]. 
Level 1 evidence demonstrating a survival benefit 
recommended neoadjuvant cisplatin-based chemotherapy 
[7,8]. However, the use of neoadjuvant chemotherapy (NAC) 
is low for various reasons, and clinicians must frequently 
decide whether to recommend adjuvant chemotherapy (ACH) 
for moderate-to-high-risk patients who have not received 
NAC [9-11]. ACH following local treatment has resulted in 
increases in survival rates of patients with solid tumors [12]. 
Although randomized clinical trials (RCTs) investigating 
the effect of ACH after RC in patients with MIBC have 
been performed [13-18], the effects of ACH for management 
of MIBC remains controversial [7]. There have been several 
meta-analysis evaluating the effects of  ACH on MIBC 
patients [6,8,9], but no study has evaluated the effects of 
ACH on locally advanced MIBC. Moreover, MIBC reflects 
very broad disease status, and locally advanced MIBC (pT3+ 
and/or pN+) is known to exhibit much poorer prognosis 
than localized MIBC (pT2pN0). For these reasons, we aimed 
to examine the effects of ACH on improvement of survival 
outcomes in patients with locally advanced MIBC following 
RC. 
MATERIALS AND METHODS
1. Search strategy
We performed computerized bibliographic search 
of  PubMed/MEDLINE, Embase, and Cochrane library 
databases in February 2018. We used search terms, such 
as ‘urinary,’ ‘bladder,’ ‘carcinoma,’ ‘cancer,’ ‘chemotherapy,’ 
‘adjuvant,’ and relevant variants. Conference abstracts were 
excluded even if  they met the eligibility criteria. In the 
current study, we only included trials that were published 
in English. The search included 1,575 articles. Two authors 
(DKK and YSH) independently reviewed the titles and 
abstracts based on the inclusion criteria, and reviewed the 
identified articles. 
2. Trial inclusion criteria
The eligibility of  a study was evaluated with consi-
deration of  the participants, interventions, comparators, 
outcomes, and study design (PICOS) approach and the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [19]. We def ined 
study population and intervention as patients with locally 
advanced MIBC who underwent RC and ACH, respectively. 
Comparator was defined as RC alone. The outcomes mea-
sured were progression-free survival (PFS) and overall 
survival (OS) rates. The following inclusion criteria were 
used: (1) RCT; (2) not animal research; (3) patients with 
locally advanced MIBC who underwent RC; (4) ACH; (5) 
values reported for the PFS and OS outcomes; and (6) 
availability of  Kaplan-Meier/uni- or multi-variate Cox 
proportional hazard model results to estimate hazard ratios 
(HRs) and 95% confidence intervals (CIs). 
3. Data extraction
Two authors (DKK and YSH) independently reviewed 
included articles and extracted the data for each trial. 
Data were extracted at the trial level. Any discord of 
extracted data between two authors was resolved through 
consensus. Extracted data included details on study design, 
inclusion and exclusion criteria, randomization, participant 
demographic and oncologic characteristics, treatment 
characteristics (regimen, dosage, planned cycles of ACH, and 
median follow-up period), outcomes measured (PFS and OS), 
and results (numbers of events, HRs, 95% CIs, and p-values).
The primary endpoint was PFS; progression was defined 
as distant metastasis or local recurrence at the surgical 
site or local lymph node after RC or randomization. The 
secondary endpoint was OS, which was defined as the 
interval between RC or randomization and death from 
MIBC or any other cause.
4. Study quality assessments
In individual studies, the risk of bias was assessed using 
tools recommended in recent meta-analysis guidelines that 
assessed aspects of RCT design and implementation [20,21]. 
The risk of bias assessment included examination of the 
use of random sequence generation, allocation concealment, 
blinding of participants and researchers, blinding of outcome 
assessment, incomplete outcome data, and selective reporting.
We evaluated the certainty of comparisons using Grad-
ing of Recommendations, Assessments, Developments, and 
Evaluation (GRADE) system that provides a systematic 
approach to evaluation of  the quality of  evidence and 
strength of  recommendations [21]. GRADE consisted of 
methodology, precision, consistency, directness, and risk 
of  publication bias. Based on these criteria, we assessed 
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evidence of  meta-analysis by classifying the quality of 
evidence on four levels of high, moderate, low, and very low. 
5. Statistical analysis
The effects of ACH on outcomes were measured using 
HRs. Log HR values were obtained directly from the trials 
reporting HR point estimates and CIs, and the standard 
errors of  log-HRs were calculated using the published 
CIs [22]. Some studies reported Kaplan-Meier log-rank or 
Wilcoxon p-values; however, they did not include HRs or 
95% CIs, or both. In these cases, we estimated HRs and 95% 
CIs using p-values, numbers of total events, and numbers 
that were randomized to each arm [23]. Estimates for the 
included studies were then combined using a random 
effects model with inverse variance [24]. Pooled HRs with 
95% CIs indicated the effects of ACH on OS and PFS. Chi-
square heterogeneity tests were used to test for statistical 
heterogeneity between trials. The I2 statistic was calculated 
to measure discrepancies between clinical trials [25]. A 
Cochran Q statistic p-value <0.05 or an I2 statistic >50% 
were used to indicate the presence of statistically significant 
heterogeneity between RCTs [21]. We assessed the stability of 
results when each included study was sequentially excluded 
for sensitivity analysis. The Egger linear regression and 
funnel plots were used for evaluation of publication bias. 
Symmetry reversal funnel diagrams did not show significant 
publication bias; If the bias exists, the inverted funnel plots 
should appear distorted and asymmetrical. Additionally, 
significant statistical publication bias was suspected when p 
value was less than 0.05 on Egger's test.
We used Review Manager v.5.1 (2008; Nordic Cochrane 
Center, Cochrane Collaboration, Copenhagen, Denmark) 
for performing meta-analysis. All p-values were two-sided; 
and except for the test of discrepancy, p-value <0.05 was 
considered statistically significant. 
RESULTS
1. Systematic review process
The results for PRISMA flow diagram are presented in 
Fig. 1. The initial database search found 1,575 articles; among 
them, 1,315 remained after duplicates were removed. We 
then examined the titles and abstracts; through this review, 
1,273 articles were excluded. After that, analysis of  full-
text articles was performed based on the inclusion criteria. 
Four RCTs with a total of 490 patients were included in this 
study [14,15,18,26]. 
The information for the included studies is pre sented 
in Tables 1 and 2 [14,15,18,26]. All included trials were 
prospective RCTs. One study was performed in Europe [15], 
two studies were performed in the United States [14,26], and 
one study was a multicenter RCT that included patients 
from Europe and Canada [18]. Four trials enrolled patients 
with locally advanced MIBC (pT3-4 and/or pN+ and M0). 
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tematic reviews and meta-analysis flow-
chart. RCT, randomized controlled trial; 
MIBC, muscle-invasive bladder cancer.
67Investig Clin Urol 2019;60:64-74. www.icurology.org
ACH in bladder cancer
The chemotherapy regimens used varied between studies. 
Three or four cycles of ACH were used in most of the trials.
2. Primary endpoint: PFS
Meta-analysis of the included trials revealed an overall 
HR of 0.48 for PFS for ACH (p<0.00001; 95% CI, 0.39–0.60; Fig. 
2A). Results indicated that the among-study heterogeneity 
was statistically significant (Cochran Q statistic, p=0.65; I2 
statistic, 0%). The absolute increases in PFS for all trials was 
17%, respectively (i.e., equivalent to numbers needed to treat 
of 5.9, respectively).
3. Secondary endpoint: overall survival
Analysis of  the random-effects model revealed that 
pooled HR across all studies was 0.63 (p=0.0009; 95% CI, 0.48–
0.83; Fig. 2B); among-study heterogeneity was not statistically 
significant (Cochran Q statistic, p=0.28; I2 statistic, 22%). The 
absolute increase in OS for all trials was 10%, respectively (i.e., 
equivalent to numbers needed to treat of 10, respectively).
4. Sensitivity analyses
Sensitivity analysis was performed using sequential 
exclusion of studies to evaluate the effect of each study on 
overall meta-analysis results. Trial by Sternberg et al. [18] 
had the greatest negative effects on both PFS and OS HRs. 
Study by Lehmann et al. [15] had the largest positive effects 
on PFS, and Skinner et al. [26] showed the largest positive 
effects on OS HRs, respectively. Exclusion of any one study 
did not result in any statistically significant changes in the 
results. Results were statistically reliable.
5. Publication bias
For both PFS and OS, significant publication bias was 
not observed in statistical tests. Funnel plots for publication 
bias for PFS and OS showed a certain degree of symmetry 
(Fig. 3). Furthermore, the Begg’s tests also demonstrated that 
there was no statistical evidence of publication bias in this 
meta-analysis of PFS (p=0.214) and OS (p=0.717).
6. Quality assessment and qualitative risk of bias
Results for the risk of bias assessment and graph are 
shown in Figs 4. and 5. There were two main sources of 
bias. The first source was unblinded study design, which 
would cause bias in the results towards ACH. The second 
source was early trial termination. The reasons for early 
discontinuation was showing ACH effect to be greater [15]. 
Early discontinuation of a trial was included as other bias.
The results of  GRADE quality assessment of  direct 
evidence of each comparison are shown in Table 3. Certa inty Ta
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was moderate in all of the two comparisons.
DISCUSSION
ACH has been used to manage MIBC, to eradicate 
micrometastatic lesions, and to enhance postoperative 
survival outcomes [27-29]. The main advantage of  ACH 
after RC is that after assessing pathologic primary tumor 
and regional lymph node categories, clinicians can choose 
patients with highest risk for recurrence who are most 
likely to benefit from ACH without delay in defi nitive 
treatment. Several RCTs have been performed to investigate 
the effects of ACH in patients with MIBC [14,26,30-34]. Meta-
analyses have found statistically significant evidence for 
the benefits of ACH use for OS and PFS in these patients 
[6,8,9]. However, these studies had limitations, such as small 
sample sizes, early patient entry interruption, analysis and 
terminology confusion, and questionable interpretation of 
results [35,36]. We focused on trials regarding the effect of 
ACH on locally advanced MIBC patients only, and conducted 
a meta-analysis of these papers through systematic review.
We found a positive benefit of  ACH on PFS and OS 
compared to no ACH, following RC in patients with locally 
advanced MIBC. We reported a 52% relative risk reduction 
in progression and a 48% reduction in the risk of death. 
Leow et al. [9] used a meta-analysis to examine the effects of 
Fig. 2. (A) Forest plots of PFS in locally advanced MIBC (pT3-4 and/or pN+ and M0), (B) forest plots of OS in locally advanced MIBC (pT3-4 and/or pN+ and 
M0). PFS, progression-free survival; MIBC, muscle-invasive bladder cancer; OS, overall survival; SE, standard error; CI, confidence interval; df, degrees of 
freedom; ACH, adjuvant chemotherapy.
Study or subgroup Log [hazard ratio] Weight (%)
Skinner 1991
Freiha 1996
Lehmann 2006
Sternberg 2015
Total (95% CI)
Heterogeneity: Tau =0.00; Chi =1.65, df=3 (p=0.65); I =0%
Test for overall effect: Z=6.43 (p<0.00001)
2 2 2
-0.7571
-0.8990
-1.0438
-0.6161
24.1
10.5
11.0
54.3
100.0
0.47 [0.30, 0.74]
0.41 [0.21, 0.81]
0.35 [0.18, 0.69]
0.54 [0.40, 0.73]
0.48 [0.39, 0.60]
SE
Hazard ratio
IV, random, 95% CI
A
0.2301
0.3484
0.3401
0.1534
Favours [ACH] Favours [control]
Hazard ratio
IV, random, 95% CI
100.1 10.2 0.5 52
Study or subgroup Log [hazard ratio] Weight (%)
Skinner 1991
Freiha 1996
Lehmann 2006
Sternberg 2015
Total (95% CI)
Heterogeneity: Tau =0.02; Chi =3.85, df=3 (p=0.28); I =22%
Test for overall effect: Z=3.32 (p=0.0009)
2 2 2
-0.7977
-0.3647
-0.5596
-0.2484
27.3
12.8
17.1
42.8
100.0
0.45 [0.29, 0.71]
0.69 [0.34, 1.43]
0.57 [0.31, 1.05]
0.78 [0.56, 1.08]
0.63 [0.48, 0.83]
SE
Hazard ratio
IV, random, 95% CI
B
0.2332
0.3684
0.3121
0.1675
Favours [ACH] Favours [control]
Hazard ratio
IV, random, 95% CI
100.1 10.2 0.5 52
Table 2. Treatment characteristics of included studies
Trial
Median age, 
range (y) 
Interval between 
RC and ACH
Number of 
surgeon
Surgical 
type of RC
ACH
regimens
ACH dose
(mg/m2)
No. of 
planned 
cycles
Skinner et al. [26] Control: 62, 30–73 
ACH: 61, 22–75 
6 wk 3 Open CAP C 100, A 60, P 600 4
Freiha et al. [14] Control: 64 (mean), 49–78 
ACH: 59 (mean), 40–76 
6 wk NA NA CMV C 100, M 30, V 4 4
Lehmann et al. [15] Control: 62.7 
ACH: 58.8 
NA NA NA MVAC
   or MVEC
M 30, V 3, A 40, C 70
M 30, V 3, E 45, C 70
3
Sternberg et al. [18] Control: 61, 37–76 
ACH: 61, 35–82 
90 d NA NA MVAC
   or GC
M 30, V 3, A 30, C 70
G 1000, C 70
4
RC, radical cystectomy; ACH, adjuvant chemotherapy; NA, not available; CAP, cisplatin, doxorubicin and cyclophosphamide; CMV, cisplatin, meth-
otrexate and vinblastine; MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; MVEC, methotrexate, vinblastine, epirubicin and cisplatin; 
GC, gemcitabine and cisplatin; C, cisplatin; A, doxorubicin; P, cyclophosphamide; M, methotrexate; V, vinblastine; E, etoposide; G, gemcitabine.
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adjuvant cisplatin-based chem otherapy after RC in patients 
with MIBC. They found that ACH improves disease-free 
survival and OS rates by 34% and 22%, respectively. Vale et 
al. [8] also found that ACH improves disease-free survival 
and OS rates of  patients with MIBC by 32% and 25%, 
respectively. After comparing these results with ours, we 
found that our analysis showed ACH may be more effective 
in locally advanced MIBC patients than in MIBC patients. 
This study supports the possibility that beneficial effects of 
ACH may be greater for locally advanced MIBC patients. 
Another difference between previous meta-analyses [6,8,9] 
and ours was the exclusion of conference abstracts. The two 
conference abstracts included in previous meta-analyses 
have not been fully published [31,32]. Results published 
in abstracts were often very diffe rent from the results 
published in full-length articles; abstracts were generally not 
subjected to the strict peer review process typically required 
for journal articles. Therefore, unconfirmed bias may 
have affected the results of systematic reviews, including 
abstracts [37]. The Agency for Healthcare Research and 
Quality does not recommend the use of  conference and 
meeting abstracts for evaluating selective outcome reporting 
and selective analysis reporting, given the variability in 
degree of agreement between conference abstracts and their 
subsequent full-text publications [38]. 
Our study did have some limitations. Since access to 
individual patient data was not possible, addi tional survival 
analyses could not be performed for similar covariates. 
There were also some between-trial differences in definitions 
of the endpoints (PFS and OS). Two trials defined it as time 
from RC until the earliest occurrence of relapse or death 
from any cause [14,26]. Other trials defined it as the time 
from randomization [15,18]. Another important limitation 
in this study was that the defects from earlier trials could 
have affected the outcomes. Two trials were discontinued 
early due to beneficial interim results [14,15], which could 
have affected the results of a later meta-analysis [8]. In two 
trials, approximately one-quarter of the patients randomized 
to treatment group did not receive chemotherapy [15,26]. 
Lehmann et al. [15] also had serious methodological fault. 
Most of  control group patients with disease progression 
did not receive chemotherapy for recurrence; one-third of 
treatment group patients also did not receive chemotherapy 
[9]. The most significant effect of these design flaws was 
likely dilution of  the positive and negative effects of 
Fig. 3. Funnel plots for publication bias. (A) Progression-free survival. (B) Overall survival.
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chemotherapy. 
Level 1 evidence supports the use of NAC to improve 
OS of patients with MIBC, but adoption rates remain low 
[39]. Cowan et al. [10] used a survey to determine factors 
related to NAC use, define reasons for low utilization, and 
the current rate of  NAC use among urologic oncologists. 
They found NAC adoption rates between 30% and 57%, 
although the urologic oncologists discussed NAC with >90% 
of their patients and medical oncologists recommended NAC. 
Among major concerns regarding the use of NAC, age and 
comorbidities accounted for the greatest proportion, followed 
by delay in surgery, marginal benefit, prolonged diagnosis 
and referral, better adjuvant therapy choices, too toxic for 
surgical patient, and risk of surgical compli cations. The use 
of  NAC can have negative effects on assessing response 
to therapy, due to discrepancies between interpretation of 
clinical and pathologic stages; patient is then more likely to 
receive unnecessary treatment. Despite the availability of 
level 1 evidence, use of NAC and ACH for bladder cancer 
(BCa) remains low [9,40,41]. Expectedly, chemotherapy use 
is even lower for upper tract urothelial carcinoma (UTUC), 
due to the absence of corresponding strong evidence [42]. 
Therefore, the outcome of  ongoing Phase II/III clinical 
trial was enthusiastically anticipated, and perioperative 
chemotherapy versus surveillance in upper tract urothelial 
cancer (POUT) trial recently published the results [43]. 
POUT trial addresses whether ACH improves survival 
for patients with locally advanced or node-positive UTUC 
(pT2-T4, N0-3, M0). POUT trial provides a high-level of 
evidence for the added value of  ACH in patients with 
locally advanced or node-positive UTUC. However, this trial 
was prematurely discontinued by the safety monitoring 
committee, due to significant improvement in disease-free 
survival [43]. In addition, this trial may be limited due to 
inadequate stratification of local or locoregional disease [42]. 
The National Comprehensive Cancer Network (NCCN) 
guidelines suggest that ACH may be given to patients 
with high-risk pathology who did not receive NAC (cate-
gory 2A recommendation) [44]. That is, based on relatively 
low-level evidence, there is unified NCCN agreement that 
intervention is appropriate. In patients with pT3-4 and/or N+ 
M0 disease, 5-year survival rate after RC is only 30% at most. 
As a result, ACH was administered to high-risk patients to 
delay relapse and prolong survival [45]. This approach of 
administering chemotherapy after local treatment increases 
survival in patients with many different solid tumors 
[46,47]. It also prevents overtreatment for patients who are 
suspected of having a reasonable outcome with only surgery, 
that is, those with tumor localized to the bladder [45]. A more 
sophisticated analysis of molecular prognostic and predictive 
markers by available sufficient tissue is also an advantage. 
If micrometastases are present, a clinician can treat them 
when they are at a low volume rather than waiting for an 
overt metastatic disease [45]. ACH also has disadvantages of 
delayed treatment for micrometastatic disease, and results 
in limitation of  administration of  chemotherapy due to 
postoperative morbidity [48]. There is no accurate answer to 
the question of whether ACH is less effective than NAC, 
as they both have advantages and disadvantages. No study 
directly compares the effects of both. Yin et al. [49] found 
that NAC is associated with a survival benefit (absolute 
increase of 8% OS), which is equivalent to a number needed 
to treat of 12.5. We calculated the absolute increases in OS 
by ACH in MIBC patients using a study by Leow et al. [9], 
and found a 4% increase in results (i.e., numbers needed to 
treat, 25). Our study found that the absolute increases in 
OS for use of ACH in patients with locally advanced MIBC 
was 10%, respectively (i.e., numbers needed to treat, 10). 
Fig. 5. Risk of bias graph.
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Although ACH, when used for all MIBC patients, seems to 
have a marginal benefit (4% increase), overtreatment is a 
concern (number needed to treat, 25). However, if ACH were 
offered only to patients with locally advanced MIBC, the 
number needed to treat using ACH may be lower than that 
of NAC (10 versus 12.5). Therefore, a larger collaborative 
international and well-designed RCT will be needed to 
determine the true value of postoperative chemotherapy. 
The effects of  ACH and NAC in patients with MIBC or 
locally advanced MIBC should also be compared. 
Over the past 30 years, there has been no significant 
progress in the treatment of  metastatic BCa, and che-
motherapy is still the standard of  care [50]. However, 
advances in the perception of  pathophysiology provided 
by comprehensive genomic profiling of BCa may greatly 
improve the outcomes of this malignancy [51]. The relevance 
of  PD-1 blockade in urothelial cancer has been recently 
confirmed by a phase I study to evaluate a human mono-
clonal antibody directed against PD-L1 (MPDL3280A), 
including 67 patients with metastatic BCa [52]. This trial 
verif ied the checkpoint PD-1 pathway as a promising 
therapeutic target in BCa [53]. Rapidly evolving knowledge 
of  urothelial carcinoma pathophysiology and identified 
fundamental molecular alterations will provide the basis for 
new therapies, and apply new therapeutic effects through a 
well-designed trial.
CONCLUSIONS
Our meta-analysis of four RCTs found that ACH may 
provide benefits for PFS and OS in patients with locally 
advanced MIBC who received ACH after RC, compared to 
those who underwent surgery alone. Our results, compared 
to previously reported meta-analysis, suggest that beneficial 
effects of  ACH may be greater in patients with locally 
advanced MIBC patients than in those with MIBC.
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